

B ~~6~~ 11. A pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of a compound as defined in Claim ~~1~~²¹⁻¹ and a pharmaceutically acceptable carrier.

~~7~~ 12. A pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of a compound as defined in Claim ~~2~~ and a pharmaceutically acceptable carrier.

Q2B ~~8~~ 13. A pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of a compound as defined in Claim ~~3~~²¹⁻³ and a pharmaceutically acceptable carrier.

~~9~~ 14. A pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of a compound as defined in Claim ~~4~~ and a pharmaceutically acceptable carrier.

~~10~~ 15. A pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of a compound as defined in Claim ~~5~~ and a pharmaceutically acceptable carrier.

B ~~11~~ 16. A method of treating allergic conditions in warm blooded animals which comprises administering to warm blooded animals suffering from allergic conditions an effective anti-allergic amount of a compound as defined in Claim ~~6~~²¹⁻¹.

~~12~~ 17. A method of treating allergic conditions in warm blooded animals which comprises administering to warm blooded animals

suffering from allergic conditions an effective anti-allergic amount of a compound as defined in Claim 2.

¹³
18. A method of treating allergic conditions in warm blooded animals which comprises administering to warm blooded animals suffering from allergic conditions an effective anti-allergic amount of a compound as defined in Claim 3.

¹⁴
19. A method of treating allergic conditions in warm blooded animals which comprises administering to warm blooded animals suffering from allergic conditions an effective anti-allergic amount of a compound as defined in Claim 4.

¹⁵
20. A method of treating allergic conditions in warm blooded animals which comprises administering to warm blooded animals suffering from allergic conditions an effective anti-allergic amount of a compound as defined in Claim 5.

REMARKS

The specification has been amended to refer to the PCT application on which this application is based, and to the United States applications from which the PCT application claims priority.

In the claims, Claim 6 (a multiple dependent claim) has been replaced by simple dependent claims, Claim 8 has been replaced by method-of-use claims, and Claims 7 and 10 have been canceled.

Q2
B1
Cont

78